Project Grant R01HL175424
Award Date
5/15/25
Completion Date
2/28/29
Dollars Obligated
$817K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This $122,625 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to identify small molecule compounds that can activate the SIRT1 protein and thereby inhibit the progression of aortic aneurysms in Marfan syndrome patients. The key research activities include in silico screening of a molecular library to identify promising SIRT1 activating compounds, followed by in vitro testing of these...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837), provides $705,944 to Yale University to conduct research on the mechanisms underlying thoracic aortopathy, which is a leading cause of morbidity and mortality. The research aims to elucidate the molecular, cellular, and biomechanical factors that drive the development and progression of aortic aneurysms, dissections, and ruptures,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $2,508,095 to Yale University to conduct research on the underlying mechanisms of thoracic aortic disease. The overarching goal is to elucidate how aberrant interactions between vascular cells and the extracellular matrix lead to the progressive deterioration of the thoracic aorta, potentially resulting in aortic dilatation, dissection,...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $740,338 to the University of Cincinnati to study the role of Protease Activated Receptor 2 (PAR2) in the initiation and progression of abdominal aortic aneurysm (AAA). The research aims to determine the effect of VSMC-specific PAR2 deletion and PAR2 inhibition in mouse models of aneurysmal disease, as well as delineate how PAR2...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $715,180 in funding to Baylor College of Medicine to study the epigenetic regulation of trained immunity in thoracic aortic aneurysms and dissections. The research aims to: 1) determine the sites and epigenetic signatures of trained immunity in monocytes/macrophages in the aortic wall and bone marrow in animal models and patients; 2) assess...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Program (CFDA 93.837) provides $705,279 to Boston University to investigate the effects of environmental pollutants on the cardiovascular system. The research aims to characterize how lipophilic pollutants and "forever chemicals" impact vascular function, angiogenesis, and inflammation, with a focus on understanding the pathogenic mechanisms involving...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will provide $703,358 to Tufts Medical Center Parent, Inc. over the period of August 22, 2024 to May 31, 2028. The award will support research to investigate the role of the FHOD3 gene variant in regulating autophagy pathways and their impact on the development of hypertrophic cardiomyopathy and heart failure. The project will leverage...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), supports research under the Cardiovascular Diseases Research program (CFDA 93.837). The $169,560 grant awarded to the Regents of the University of Michigan aims to investigate the role of the PERK/EIF2A/ATF4 endoplasmic reticulum stress response and MLL1-mediated regulation of CHOP gene expression in vascular smooth muscle cell (VSMC) apoptosis and...
This $1,927,989 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports research to understand the molecular mechanisms and develop novel therapeutic approaches for congenital aortic valve disease. The research will utilize a newly developed mouse model that recapitulates the human condition of congenital aortic valve stenosis. The objectives are to define the cell-specific pathways underlying...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), will support research to determine how hyperglycemia affects aortic biomechanics and mechanobiology, and whether restoring normoglycemia can reverse these changes. The total funding amount is $126,442, with the award period running from September 1, 2024 to August 31, 2026. The research will be conducted by the Regents of the University of...